Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (NasdaqGS:HQY) from Outperform to Strong Buy. Analyst Price Forecast Suggests 31.89% Upside As of March 19, ...

HealthEquity stock’s recent year-to-date underperformance is partly due to its disclosure of fraud against some of its HSA customers and near-term investor concerns about recent management changes.

On this news, HealthEquity shares fell 17% on March 19, 2025.

Royal Bank of Canada lifted their price objective on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Mizuho started ...

Raymond James upgraded HealthEquity (HQY) to Strong Buy from Outperform with a price target of $115, down from $120. The firm upgrade the ...

Over the past few days HealthEquity (NASDAQ: HQY) shares have been rather sickly. The health savings account (HSA) specialist's stock was rocked by a disappointing earnings report, and as a result ...

Seeking Alpha Investing Group Leader Quad 7 Capital attributed the selloff to a mixed earnings report and the stock’s premium valuation. While HealthEquity's (NASDAQ:HQY) Q4 revenue jumped ~19% ...

Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (BMV ... VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,744K shares ...

These fell short of expectations on several metrics. HealthEquity divulged its fourth-quarter and full-year fiscal 2024 results just after market close on Tuesday. These showed that the company ...